TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2250 participants.

Also called NCT07052903

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07052903
  • EU CT 2024-519917-72-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, France, Germany, Greece, Hong Kong SAR China, Hungary, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07052903. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-02 (actual); primary completion 2030-05-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Condition
Transthyretin Amyloidosis With Cardiomyopathy
Intervention (Drug)
Nucresiran
Intervention (Drug)
Sterile Normal Saline (0.9% NaCl)
Lead sponsor
Alnylam Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07052903
Content hash
ea6fc88e4837d657a966ef2daa89ee92886d2acf7cb440e143a60e5bbd32508c